HTLV-III SEROCONVERSION ASSOCIATED WITH HEAT-TREATED FACTOR VIII CONCENTRATE
- 15 March 1986
- journal article
- other
- Published by Elsevier in The Lancet
- Vol. 327 (8481), 611-612
- https://doi.org/10.1016/s0140-6736(86)92828-x
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Primary Human T-Lymphotropic Virus Type III InfectionAnnals of Internal Medicine, 1985
- INACTIVATION OF HTLV-III/LAV DURING PLASMA FRACTIONATIONThe Lancet, 1985
- ABSENCE OF ANTIBODIES TO LAV/HTLV-III IN HAEMOPHILIACS TREATED WITH HEAT-TREATED FACTOR VIII CONCENTRATE OF AMERICAN ORIGINThe Lancet, 1985
- Detection of Antibodies to Human T-Cell Lymphotropic Virus-III (HTLV-III) with an Immunoassay Employing a Recombinant Escherichia coli-Derived Viral Antigenic PeptideBio/Technology, 1985
- Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.JCI Insight, 1985
- INABILITY OF PASTEURISED FACTOR VIII PREPARATIONS TO INDUCE ANTIBODIES TO HTLV-III AFTER LONG-TERM TREATMENTThe Lancet, 1985
- ABSENCE OF ANTIBODIES TO AIDS VIRUS IN HAEMOPHILIACS TREATED WITH HEAT-TREATED FACTOR VIII CONCENTRATEThe Lancet, 1985